Among patients with AKI

Among patients with AKI, CKD developed within two years in 72.1 percent of patients. These findings suggest that AKI may initiate CKD . In addition, AKI patients were 6.74 times more likely to develop ESRD than those without injury.

The papers on which the LSUHSC public health faculty are co-authors are Incidence of in situ and invasive vulvar cancer in the U.S., 1998-2003 , Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States African-American womenden of human papillomavirus-associated anal cancers in the U.S. , Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the U.S., 1998-2003 and cancer registries and monitoring the impact of prophylactic HPV vaccines: The potential role . – ‘The Louisiana Tumor Registry, housed in the LSUHSC School of Public Health has the scientific infrastructure and expertise to monitor and evaluate the impact of HPV vaccination on the community,’says Vivien W. Director of Louisiana Tumor Registry at LSU Health Sciences Center New Orleans School of Public Health. ‘and and mortality among African-American women in Louisiana much higher than the two rates of Louisiana white women and other African-American women in the United States,’said Xiao Cheng Wu, Associate Professor of Public Health and Associate Director of the Louisiana tumor Registry at LSU Health Sciences Center New Orleans.

read more

The University of HealthSystem Consortium , an alliance 103 academic medical centers to 210 their affiliated hospitals, supported the Obama administration is call for action by imploring focusing every hospital in nurses retention of, particularly during the economic downturn.

A teamWorldAbout of researchers led by Fadi Fakhouri, from Imperial College in London, recent tested the effect of rituximab led is an antibody facing to B cell that was initially developed for the treatment of non-Hodgkin’s lymphoma for patients with lupus nephritis. The study in retrospect evaluated the long-term efficacy and safety of rituximab into 20 SLE patient with heavy lupus nephritis. According to any average follow-up of 22 months, renal improvements been views in 12 patients .